Infants Receiving a Single Dose of Nirsevimab to Prevent RSV Do Not Have Evidence of Enhanced Disease in Their Second RSV Season

Research output: Contribution to journalArticlepeer-review

Abstract

To characterize nirsevimab in the prevention of RSV, children from the Phase 3 MELODY trial were followed through their second RSV season. No increase in medically attended RSV lower respiratory tract infections or evidence of antibody-dependent enhancement of infection or disease severity was found for nirsevimab vs placebo recipients.

Original languageAmerican English
Pages (from-to)144-147
Number of pages4
JournalJournal of the Pediatric Infectious Diseases Society
Volume13
Issue number2
DOIs
StatePublished - 1 Feb 2024

Keywords

  • immunization
  • monoclonal antibody
  • nirsevimab
  • respiratory syncytial virus

All Science Journal Classification (ASJC) codes

  • General Medicine

Fingerprint

Dive into the research topics of 'Infants Receiving a Single Dose of Nirsevimab to Prevent RSV Do Not Have Evidence of Enhanced Disease in Their Second RSV Season'. Together they form a unique fingerprint.

Cite this